Browsing by Author "Alshammari, Naif"

Now showing 1 - 2 of 2

Restricted
Comparative Analysis of Stablecoin Market Capitalization
(University of Sussex, 2024) Alshammari, Naif; Alexander, Carol
This paper takes a closer look at the market capitalization trends for the five most popular stablecoins: Tether, USD Coin, Dai, TrueUSD, and PAX Gold. Stablecoins are digital currencies whose price volatility is minimized since their value is pegged to an underlying asset, such as a fiat currency or commodity. Despite the ever-growing importance, very little research has been done to explain the factors affecting their market capitalization and what this means for the general financial market. The design of the research applies an empirical study with a quantitative approach in analyzing historical data of the market capitalization for these stablecoins over a defined period. In the analysis, it identifies major determinants of the market capitalization: regulatory developments, rates of adoption, technological advancements, and macroeconomic conditions. The study further shows comparative stability and growth patterns among the chosen stablecoins and gives insight into which performs better relatively in the cryptocurrency marketplace. The results indicate there were major differences in the trends of market capitalization for studied stablecoins, thus evidence of the impact from exogenous variables such as regulatory change and changes in market demand. In the light of this, the study finds that it is very important to stakeholders, including investors, policy makers, and financial analysts, that these factors are understood well to make informed decisions within the fast-changing landscape of digital currencies. This work thus adds value to the literature base with meaningful insights into the dynamics of stablecoin market capitalization, with implications for the future of digital financial assets.
45 0
Restricted
Improving Supplier Relationship Management for Sustainable and Resilient Sourcing in the Global Pharmaceutical Supply Chain: A Case Study of GlaxoSmithKline (GSK)
(Saudi Digital Library, 2025) Alshammari, Naif; Zhou, Zhou
In the pharmaceutical industry, the complexity of global supply chains and the pressure for regulatory compliance create significant challenges for Supplier Relationship Management (SRM). While traditional procurement has often focused on cost control and auditing, there is an increasing necessity to pivot toward more collaborative, innovation-driven, and sustainable practices. This dissertation critically evaluates the SRM practices of GlaxoSmithKline (GSK) to identify how the firm can better leverage its supplier relationships to enhance sustainability, resilience, and ethical performance. Adopting an interpretivist and inductive case study design, this research analyzes secondary qualitative data, including GSK’s sustainability and business performance reports, supplier codes of conduct, and industry analyses. By synthesizing theoretical frameworksincluding the Kraljic Portfolio Model, the Triple Bottom Line, and resilience literaturethe study examines the integration of sustainability and resilience into GSK’s supplier governance. The findings indicate that while GSK exhibits a mature governance structure for compliance and risk management, its approach remains predominantly transactional and control-oriented. Significant gaps exist in fostering deep relational collaboration and co-innovation, which are essential for meeting ambitious environmental goals and navigating supply chain shocks. To bridge these gaps, the dissertation proposes a transition toward a more collaborative and digitally enabled SRM model. Recommendations focus on moving beyond compliance-based monitoring to implement joint capability building, strategic knowledge sharing, and the integration of sustainability and resilience metrics into supplier performance scorecards. This research contributes to SRM theory by extending its application to a highly regulated, sustainability-demanding industry and provides actionable managerial insights for pharmaceutical procurement professionals.
8 0